EisenbergDMDavisRBEttnerSL. Trends in alternative medicine use in the United States, 1990‐1997: results of a follow‐up national survey. JAMA. 1998;280:1569‐1575.
2.
GoswamiRMondalAMTomarN. Presence of 25(OH)D deficiency and its effect on vitamin D receptor mRNA expression. Eur J Clin Nutr. 2009;63:446‐449.
3.
ThompsonIMTangenCMGoodmanPJLuciaMSKleinEA. Chemoprevention of prostate cancer. J Urol. 2000;182(2):499‐507; discussion 508.
4.
YinLGrandiNRaumEHaugUArndtVBrennerH. Meta‐analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009;30:113‐125.
5.
AliMMVaidyaV. Vitamin D, cancer. J Cancer Res Ther. 2007;3:225‐230.
6.
ArnsonYAmitalHShoenfeldY. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66:1137‐1142.
7.
Wu‐WongJR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol. 2009Apr9. [Epub ahead of print].
8.
BinkleyN. Is vitamin D the fountain of youth?Endocr Pract. 2009Jun2:1‐25. [Epub ahead of print]
9.
AutierPGandiniS. Vitamin D supplementation and total mortality: a meta‐analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730‐1737.
10.
ViethR. What is the optimal vitamin D status for health?Prog Biophys Mol Biol. 2006;92:26‐32.
11.
HolickMF. Vitamin D deficiency. N Engl J Med. 2007;357:266‐281.
12.
PrenticeA. Vitamin D deficiency: a global perspective. Nutr Rev. 2008;66(suppl 2):S153‐S164.
13.
ThomasMKLloyd‐JonesDMThadhaniRI. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777‐783.
14.
KulakCABorbaVZBilezikianJPSilvadoCEPaolaLBoguszewskiCL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr. 2004;62:940‐948.
15.
NaganoNFukushimaN. Pharmacological and clinical trial data on a novel phosphate‐binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients [in Japanese]. Nippon Yakurigaku Zasshi. 2003;122:443‐453.
16.
MaurinN. Heparin resistance and antithrombin deficiency [in German]. Med Klin (Munich). 2009;104:441‐449.
17.
NegoroSIzumiSFurukuboT. Interaction between activated VD3 and Ca channel blockers in patients undergoing hemodialysis. Int J Clin Pharmacol Ther. 2007;45:186‐187.
